Recent Updates
Recently added Catalysts
XFOR Positive Sentiment

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

Wednesday, March 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: X4 Pharmaceuticals will participate in a fireside chat at the Leerink Global Healthcare Conference on March 11, 2026. The event will showcase the company's commitment to improving the lives of patients with rare hematology diseases. X4 is currently conducting a pivotal Phase 3 trial for its drug mavorixafor, which has received FDA Fast Track designation.
Price reaction · baseline $3.33 (2026-03-03 close) · hit pre-market · clean, no other XFOR news in the window
day 0 close
+5.1%
day 1
+11.1%
day 3 · peak
+24.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • X4 Pharmaceuticals is participating in a notable healthcare conference.
  • The company is focused on rare hematology diseases, addressing significant unmet needs.
  • Mavorixafor has received Fast Track designation from the FDA.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+171%
120-day peak, hindsight
Typical move
11.1%
average across 3 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
X4P-001
Phase 2 · WHIM Syndrome

Full Press Release Details

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) --X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami, FL.
A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section:Events and Presentations.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visitwww.x4pharma.com.

X4 Investor Contact:Remy BernardaJenny KobinIR Advisory Solutionsir@x4pharma.com

Source: X4 Pharmaceuticals, Inc.

Frequently Asked Questions

When is X4 Pharmaceuticals participating in the conference?

X4 Pharmaceuticals will participate in the conference on March 11, 2026.

What is the focus of X4 Pharmaceuticals?

X4 Pharmaceuticals focuses on rare hematology diseases and innovative therapies.

What is mavorixafor?

Mavorixafor is an orally available CXCR4 antagonist developed by X4 Pharmaceuticals.

What designation has the FDA granted mavorixafor?

The FDA has granted Fast Track designation to mavorixafor for chronic neutropenia.

ShareAdd on Google
Tags: XFOR Viatris Investor Conferences Healthcare X4 Pharmaceuticals Leerink Conference mavorixafor chronic neutropenia
Last updated: Mar 4, 2026

Biotech snapshot

Cash runway
$208M liquidity · $7M/mo burn
~30 mo
Minimal dilution risk
Lead asset
X4P-001Phase 2
WHIM Syndrome →

Catalyst track record

+171%
best trade around XFOR's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for XFOR.

See every catalyst's timing & PoA →